Scarica l'app Stockscreener
29.15
2.83%
-0.85
Dopo l'orario di chiusura:
29.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Stoke Therapeutics Stock (US86150R1023): Analyst Sentiment and Valuation Come Into Focus - AD HOC NEWS
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Rhenman & Partners Asset Management AB Lowers Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Trading Up 1.6%Should You Buy? - MarketBeat
STOK: Durable efficacy and cognitive gains position zorevunersen for a focused U.S. launch by 2028 - TradingView
The Technical Signals Behind (STOK) That Institutions Follow - Stock Traders Daily
Stoke Therapeutics (STOK) director receives grant of 17,786 stock options - Stock Titan
[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity - Stock Titan
Stoke Therapeutics (STOK) director granted 17,786 stock options at $29.46 - Stock Titan
Stoke Therapeutics (STOK) director awarded 17,786 options at $29.46 strike - Stock Titan
Stoke Therapeutics (STOK) director granted options to buy 17,786 shares - Stock Titan
Stoke Therapeutics (STOK) director receives grant of 17,786 stock options at $29.46 - Stock Titan
Stoke Therapeutics (STOK) forms 'hammer chart pattern': Time for bottom fishing? - MSN
Stoke Therapeutics Stockholders Approve Directors and Governance Items - TipRanks
Stoke Therapeutics (NASDAQ: STOK) 2026 meeting elects all directors - Stock Titan
STOK: Lead therapy delivers durable seizure and cognitive benefits, with pivotal data due mid-2027 - TradingView
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeutics Inc (STOK) - GuruFocus
Insider Sell Alert: Barry Ticho Sells Shares of Stoke Therapeuti - GuruFocus
Stoke Therapeutics (STOK) CMO sells 1,795 shares under 10b5-1 plan - Stock Titan
Stoke Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Stoke Therapeutics Advances Dravet Syndrome Clinical Trials Following Positive Results - asatunews.co.id
Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business Updates - Insider Monkey
Stoke Therapeutics (STOK) Pulls Back: Support Test Looms After 2.21% DeclineMoving Average Crossovers - The Legal Advocate
STOK Analyst Consensus - Investing.com Australia
STOK Corporate Insider Activity - Investing.com Australia
Stoke Therapeutics to Present at Upcoming Investor Conferences in June - Business Wire
Precision Trading with Stoke Therapeutics Inc. (STOK) Risk Zones - Stock Traders Daily
Stoke Therapeutics (STOK) Edges Lower: Mixed Signals Near Key ResistanceInstitutional Sentiment - The Legal Advocate
UBS Group AG Decreases Stock Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Nathan Lee Starts New Role as Vice President, Commercial Manufacturing at Stoke Therapeutics - hrtoday.in
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - TradingView
Stoke Therapeutics (STOK) Is Down 7.8% After Sharp Q1 Swing From Profit To Loss – What's Changed - simplywall.st
Zorevunersen tied to long-term benefits in Dravet syndrome - Dravet Syndrome News
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 18, 2026 - BioSpace
Lynx1 (STOK) files 13G/A reporting 4.76M shares, 8.1% stake - Stock Titan
Technical Reactions to STOK Trends in Macro Strategies - Stock Traders Daily
Stoke Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Stoke Therapeutics (STOK): Analyst Ratings and Price Target Upda - GuruFocus
Lynx1 Capital discloses 4.12M shares of Stoke Therapeutics (STOK) - Stock Titan
Redmile Group reports 4.16M shares in Stoke Therapeutics (STOK) - Stock Titan
TD Bank (NASDAQ: STOK) reports 3.18M shares, 5.4% stake - Stock Titan
RTW Funds and R. Wong report 9.99% stake in Stoke Therapeutics (STOK) - Stock Titan
Wellington affiliates hold 3.1M shares in Stoke Therapeutics (STOK) - Stock Titan
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate - Moomoo
Stoke Therapeutics Q1 earnings call highlights - MSN
HC Wainwright Analysts Boost Earnings Estimates for STOK - MarketBeat
Stoke outlines Q1 2027 rolling NDA start as EMPEROR enrollment targets June, backed by $411M cash balance - MSN
Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Progyny (PGNY) - The Globe and Mail
Stoke Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:STOK) 2026-05-11 - Seeking Alpha
BTIG Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
Stoke Therapeutics' (STOK) "Buy" Rating Reiterated at BTIG Research - MarketBeat
STOK Reiterates by BTIG -- Price Target Maintained at $39.00 - GuruFocus
Guggenheim Maintains Stoke Therapeutics(STOK.US) With Buy Rating, Maintains Target Price $60 - Moomoo
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):